New Market Research Report: China Ribonucleic Acid II (RNAII) for Injection Market, 2010-2019

From: Fast Market Research, Inc.
Published: Thu Aug 20 2015


RNAII for injection, one kind of immunomodulator, can improve body immunity and inhibit tumor by causing vacuolar degeneration and colliquative necrosis in tumor cells as well as generating large amounts of hyperplastic fibroblasts, macrophages, lymphocytes or even connective tissue to substitute tumor tissue. And it is used for the adjuvant treatment of pancreatic cancer, liver cancer, stomach cancer, breast cancer, soft tissue sarcoma and other cancers especially hepatitis B. RNAII for injection can also be used for the treatment of various diseases caused by low immune function.
According to CRI's market survey, RNAII for injection develops fast in China with sales value rising from less than CNY 60 million in 2005 to about CNY 500 million in 2014 and CAGR during this period reaching 80%.
With the lifestyle changes brought about by economic development as well as the serious environmental pollution, the incidence of cancer keeps increasing with the number of new cases exceeding 3 million each year in China. Meanwhile, there are over 90 million hepatitis B patients in China too. Therefore, the market size of RNAII for injection is expected to keep growing in the next few years in China.

Full Report Details at
- http://www.fastmr.com/prod/1020589_china_ribonucleic_acid_ii.aspx?afid=301

Readers can get at least the following information from this report:

* market size of RNAII for injection in China
* competitive landscape of RNAII for injection in Chinese market
* price of RNAII for injection made by different enterprises in China
* market outlook of RNAII for injection in China

The author suggests the following groups of people purchase this report:

* manufacturers of immunomodulator
* investors/ research institutions interested in Chinese medicine market
* any interest in the Chinese medicine market, please contact CRI for customized survey service

Companies Mentioned in this Report: Jilin Aodong Pharmaceutical Industry Group Yanji Co., Ltd, Nanjing Xinbai Pharmaceutical Co., Ltd, Xinxiang Dongsheng Pharmaceutical Co., Ltd

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156 (1.413.485.7001 Int'l)

You may also be interested in these related reports:

- China Zoledronic Acid Market, 2010-2019
- Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) Global Clinical Trials Review, H1, 2014
- Mucopolysaccharidosis II (MPS II) (Hunter Syndrome) - Pipeline Review, H2 2014
- Mucopolysaccharidosis II (MPS II) (Hunter Syndrome ) - Pipeline Review, H1 2014
- Techpool Bio-Pharma Co., LTD. - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »